Microba specializes in genetic analysis of the gut microbiome, with a bioinformatics pipeline and database that the article describes as best in its field. The company was established in 2017 by faculties of Queensland University and has accumulated research data and related intellectual property. Microba’s core product work focuses on whole-genome (shotgun) sequencing of gut microorganisms rather than 16S rRNA targeted approaches, enabling novel microorganism discovery and metabolite analysis. The company is partnering with Macrogen to co-develop a microbiome service and to build a microbiome database in Asia Pacific (including Korea, Japan, and Singapore). Microba and Macrogen plan a global service launch in early 2020 and expect to target launches in the US and Asia Pacific. Microba is pursuing licensing deals with multinational pharmaceutical companies to support therapeutics research and commercialisation.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2019